Double Bond Pharmaceutical launches Monthly Call
To start the New Year with a new level of transparency and deeper involvement of the public in the company's important processes and decisions, Double Bond Pharmaceutical is now launching a continuous competition under the name Monthly Call. Within this competition, each month the company will announce a new challenge for the public to solve or come up with a suggestion for a solution, where the best suggestion or solution will be rewarded with a price. The topic of each challenge will be directly linked to the company's daily operations and cover areas such as ideas about product and project names, monitoring of media, suggestions for changes within certain parts of company’s business essentials or comments on selected activities.
The first challenge within the framework of the Monthly Call is the following:
- Suggest the work name for FarmPharma's developmental product
This first challenge starts today, January 2, and runs until Thursday, January 31, 2019. The best suggestion will be rewarded with 10 TRISS-lottery tickets and the winner will be announced in a newsletter on February 1 and in the V-blog. To participate in the challenge, send your suggestion to info@farmpharma.se before January 31, 2019.
More about FarmPharmas product: https://www.farmpharma.se/product/
For more info, contact
Igor Lokot, CEO
Homepage: http://www.doublebp.com/
E-mail: info@doublebp.com
Blog: http://blog.doublebp.com
Follow us on LinkedIn, Facebook and Twitter!
Information on Double Bond Pharmaceutical International AB
DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in EU and globally and has a working name SI-053 in DBP pipeline. DBP has during the past year also started two subsidiaries, Drugsson AB for the distribution of fully developed human pharmaceutical and medical device products and dietary supplements in Scandinavia, and FarmPharma AB for the development of innovative veterinary products.
Tags: